A recent study has shown that moxonidine, an agonist for α2 and imidazoline 1 (I1) receptors, inhibits atherosclerosis in apolipoprotein E-deficient (ApoE−/−) mice [76], possibly via inhibiting inflammation and promoting oxidized LDL uptake and clearance (Figure 5). The gene discussed is APOE; the disease is atherosclerosis.